Maxigen Biotech Inc.

Research Maxigen Biotech Inc. (1783.TW) on Bullrun: market cap TWD 3.36B, P/E 11.6, dividend yield 5.5%. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is TWD 3.36B; P/E is 11.6; dividend yield is 5.5%.

Peer valuation comparison

Latest P/E is 11.61x versus a Healthcare sector median of 21.8x (46.7% below).

Latest dividend yield is 5.51% versus a Healthcare sector median of 2.41% (128.6% above).

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-10-18TWD 3.36B11.65.3%2

Dividend history

Latest trailing dividend snapshot: annual dividend/share 2 TWD, yield 5.5%.

About Maxigen Biotech Inc.

Maxigen Biotech Inc. researches, develops, produces, and sells implantable medical devices in Taiwan, America, Europe, rest of Asia, and internationally. It operates through two segments, Biomedical Products and Consumer Products. The company provides biomedical materials, such as collagen and bone supplements; beauty and skincare products;

Related stock research

Other Healthcare stocks

Frequently asked questions

What is Maxigen Biotech Inc.'s market cap?

Maxigen Biotech Inc.'s market capitalization is TWD 3.36B.

What is Maxigen Biotech Inc.'s P/E ratio?

Maxigen Biotech Inc.'s price-to-earnings (P/E) ratio is 11.6.

Does Maxigen Biotech Inc. pay a dividend?

Maxigen Biotech Inc. has a dividend yield of 5.5%.

What does Maxigen Biotech Inc. do?

Maxigen Biotech Inc. researches, develops, produces, and sells implantable medical devices in Taiwan, America, Europe, rest of Asia, and internationally. It operates through two segments, Biomedical Products and Consumer Products. The company provides biomedical materials, such as collagen and bone supplements; beauty and skincare products; and medical devices for ophthalmology, otolaryngology, dental, surgical, orthopedics, electronic instructions for use, and medical aesthetics, as well as engages in collagen purification activities.